MorphoSys AG accelerated the clinical development of its two top cancer drugs in the first quarter whilst also stopping work on preclinical programmes and reducing the size of its workforce. Jean-Paul Kress, the chief executive, told investors on 4 May that the company’s strategic focus is to complete development of pelabresib, a small molecule drug for myelofibrosis, and expand indications for Monjuvi (tafasitamab), an approved antibody which was launched in the US for second-line diffuse large B cell lymphoma (DLBCL) in 2020.
